Delcath Systems: Fundamental Strength Amidst Share Price Volatility

Delcath Systems, a company offering a liver-directed chemotherapy system for metastatic uveal melanoma treatment, has faced negative impacts from pricing pressure and seasonality in recent quarters. Despite this, the company's fundamentals remain intact, and its share price weakness is seen as a buying opportunity.